💧 GU Oncology — 2026-W40

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

EAU Guidelines Panel consensus statement in European Urology Oncology on testicular cancer, recommending centralization of care to specialized multidisciplinary centers. Provides actionable guidance likely to shape referral patterns and treatment center selection for advanced testicular cancer.

First-in-human phase 1 dose-finding study of the CYP11A1 inhibitor ODM-209 in heavily pretreated metastatic castration-resistant prostate cancer and advanced breast cancer, published in European Journal of Cancer. Shows PSA responses including in patients with AR-ligand-binding-domain mutations, informing further development of this steroidogenesis inhibitor.

Phase 1 trial in metastatic urothelial carcinoma, published in Journal for ImmunoTherapy of Cancer, testing an IDO1 inhibitor combined with avelumab. Showed a durable complete and partial response along with acceptable safety, providing an early efficacy signal for this immunotherapy combination.

Substantive translational science review in JAMA on cancer vaccine development, covering antigen types, delivery platforms, and approved examples like sipuleucel-T for metastatic castration-resistant prostate cancer. Provides a state-of-the-art overview that could inform understanding and future adoption of cancer vaccine therapies.

Narrative review in Annals of Surgical Oncology (Q2) on ferroptosis biology and its potential intersection with immune and radioligand therapy in metastatic castration-resistant prostate cancer. Summarizes preclinical rationale and translational gaps for future combination strategies rather than presenting new clinical data.

External validation study of the NADIR predictive model using data from the ARCHES phase 3 trial in metastatic hormone-sensitive prostate cancer treated with enzalutamide, published in Cancer. Confirms the model's ability to predict early PSA response and its association with overall survival, supporting its use to identify patients likely to benefit from ARPI therapy.

Translational biomarker analysis from a randomized phase II-III trial in advanced urothelial carcinoma, published in ESMO Open, characterizing HER1-4 expression patterns and their association with chemotherapy response. Supports further development of HER-family-targeted antibody-drug conjugates beyond HER2, though findings remain exploratory.

Retrospective pharmacovigilance analysis of FAERS reports comparing adverse event signals across advanced prostate cancer therapies, published in Current Oncology. Highlights differential toxicity profiles (e.g., cabazitaxel severity, abiraterone GI signals) that can inform agent selection and monitoring in clinical practice.

Narrative review in Cancer Treat Rev comparing cabazitaxel versus PSMA-radioligand therapy in post-docetaxel metastatic castration-resistant prostate cancer, synthesizing trial and real-world data. Discusses efficacy, safety, and PSMA-PET biomarkers to guide treatment sequencing decisions.

Retrospective biomarker analysis in metastatic urothelial cancer patients treated with first-line enfortumab vedotin plus pembrolizumab, published in European Urology (Q1). Pretreatment tumor NECTIN4 RNA expression and TMB independently associated with response and survival, suggesting potential predictive biomarkers to guide use of this standard first-line regimen.

Prospective diagnostic-performance study (Eur J Cancer) in metastatic prostate cancer comparing tumor-first DNA testing versus family-history-based referral for detecting germline pathogenic variants relevant to PARP inhibitor eligibility. Supports tumor-first workflow as a more sensitive and cost-effective strategy for triaging patients to germline testing.

Preclinical/translational study in Q1 journal identifying PPP1R14B as a driver of immunosuppression in prostate cancer, using patient-derived TCGA data and mouse models to show its knockdown enhances anti-PD-1/CAR-T efficacy. Suggests a potential future combination target but lacks clinical outcome data in treated patients.

Opinion/commentary piece in Eur Urol Oncol on triplet immunotherapy combinations in metastatic clear cell RCC. Argues against empiric biomarker-unselected triplet intensification, favoring biomarker-driven patient selection and novel mechanisms instead.

Preclinical translational study in Urologic Oncology using cell lines and xenografts identifying an AURKA-PTTG1 signaling axis driving enzalutamide resistance in prostate cancer. Mechanistic findings suggest a potential resistance pathway but lack patient-derived clinical validation, limiting immediate practice relevance.

Preclinical study in Cancer Research using prostate cancer models showing that senolytic drugs targeting BCL2/IAP pathways can eliminate chemotherapy-induced senescent cells and counter chemotherapy-driven metastatic dissemination. Provides rationale for future senolytic-chemotherapy combination trials but reports no clinical/patient outcome data.

Editorial commentary discussing a non-randomized phase 2 trial of adjuvant penpulimab with plasma multiomic biomarker analysis in very-high-risk clear cell RCC, published in Journal for ImmunoTherapy of Cancer. Suggests promise for biomarker-guided adjuvant immunotherapy but explicitly notes the exploratory, non-randomized design precludes immediate practice change.

Commentary/critical appraisal in JNCI examining how trial design (NETTER-2 in NETs, CheckMate-743/KEYNOTE-483 in mesothelioma, MAGNITUDE in prostate cancer) shapes regulatory and clinical interpretation of benefit-risk. Offers no new efficacy data but informs how oncologists should critically interpret these pivotal trials.

Retrospective single-network cohort study from the UK assessing real-world uptake, safety, and outcomes of adjuvant pembrolizumab in surgically treated clear cell RCC per KEYNOTE-564 criteria, published in European Urology Oncology. Offers practical insight into how adjuvant immunotherapy is being adopted and tolerated outside the trial setting, though sample size is modest.

Narrative/scoping preclinical review in Cancers (Q2) synthesizing mechanistic data on ultrasound-activated microbubbles combined with radiotherapy and docetaxel in prostate cancer models. Entirely preclinical/hypothesis-generating with no clinical trial data, limiting near-term practice impact.

Pharmacovigilance analysis of FAERS data in men with prostate cancer receiving androgen receptor pathway inhibitors, published in Cancers (Basel). Identifies that some darolutamide-associated safety signals (e.g., myelosuppression) may be confounded by concurrent docetaxel use, refining interpretation of adverse event reporting.

Single-institution retrospective analysis of biweekly gemcitabine plus docetaxel in heavily pretreated metastatic castration-resistant prostate cancer, published in Clin Genitourin Cancer. Suggests modest activity as a later-line option in a small real-world cohort.

Retrospective real-world cohort study in metastatic hormone-sensitive prostate cancer patients treated with enzalutamide plus ADT, published in Cancers, comparing outcomes to the pivotal ARCHES trial; highlights a substantial real-world efficacy gap that may temper expectations from trial data.